Viennese Ribbon Biolabs closes €18m Series A financing

02.02.2022
by tg

Ribbon Biolabs has cashed in €18m in Series A financing led by Hadean Ventures

New investors Lansdowne Partners, Helicase Venture as well as several undisclosed investors participated in the Series A round. Existing investors IST cube and tecnet equity also joined in the investor consortium.

Ribbon Biolabs said it will use the proceed to establish commercial-scale DNA synthesis in Europe and to expand its operations into the US. Ribbon Biolabs’ DNA synthesis technology uses an innovative approach integrating combinatorial optimisation algorithms to guide the automated enzymatic assembly of DNA

The company was founded in 2018 in Vienna to redefine the potential of synthetic DNA. The technology addresses the growing market need for synthetic DNA of sub-genomic size, up to 20 Kbp, a component for developments in biopharmaceutical research and synthetic biology.

Share

You might also like

Carbios SAS set to licence and expand PET recycling

Carbios SAS has announced "excellent outputs" from its demonstration plant in Clermont-Ferrand and its advanced engineering study for the...

Roche’s meets endpoints in relapsing multiple sclerosis

In patients with relapsing-remitting multiple sclerosis (RRMS), fenebrutinib significantly reduced the total number of new gadolinium-enhancing...

VarmX BV raises €30m in Series B2 financing

Mosaic Therapeutics closes $28m series A financing

Oncology specialist Mosaic Therapeutics Ltd will use a $28m financing to push its preclinical pipeline of targeted oncology therapies for...

Wacker AG expands biotech business through €100m acquisition

Following Wacker’s purchase of fermentation assets in the northern Spanish city of León in 2016, the chemical group now owns the entire site. The...

Macomics licences macrophage modulator to Ono

Whether Macomics Ltd nor Ono Pharmaceuticals Co Ltd disclosed any financial details about the deal under which Ono has the option to licence an...

Researchers activate chemotherapeutics by ultrasound

Chemotherapeutic treatments produce strong side effects. A new drug complex that accumulates in the tumour tissue and is only activated there by...

Sign up for our newsletter

Your e-mail-address is already registered.

Your e-mail address will be used solely for the purposes of sending out our newsletter. You will be able to unsubscribe at any time and thereby revoke your consent to receive the newsletter. A transfer of the data to third parties will not occur. For further information, please refer to our privacy policy.

Events

Advertise

PRODUCT OF THE WEEK

Bioprocess Autosampler: More Data, Less Effort

Taking samples during bioprocessing is an integral part of quality control. It allows to gather information about culture growth, medium...